Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

$IPIX Moving forward...

Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases

Excerpt...
A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;

http://www.ipharminc.com/press-release/2018/1/29/innovation-pharmaceuticals-brilacidin-franchise-anchored-in-three-clinical-indications-oral-mucositis-inflammatory-bowel-disease-and-serious-skin-infections-expands-into-dermatologic-diseases

over 20 CDA's. It only takes one partnership. Moving ahead with preps for phase 3 and IMO - potential marketing along with COMPASIONATE USE allowance.

Expanded Access and Compassionate Use

Innovation Pharmaceuticals is dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.

At this stage in our drug development program, we are evaluating the safety and efficacy profiles of three first-in-class drug candidates—Prurisol, Kevetrin and Brilacidin—to inform our understanding of their full therapeutic potential. Such work is being conducted in preparation for potential submission to the Food and Drug Administration (FDA) for drug approval, pending continued successful outcomes.

To learn more about our clinical trials, including possible opportunities to participate in ongoing or upcoming studies, visit ClinicalTrials.gov—a government-run database listing private and publicly-funded clinical studies conducted around the world.

As part of drug development, the FDA allows for potential Expanded Access / Compassionate Use of an Investigational New Drug before any regulatory approval might be achieved. This opportunity applies only to patients with serious or life-threatening conditions who are unable to participate in a clinical trial and have exhausted alternative treatment avenues.

For FDA regulations on Expanded Access / Compassionate Use, please visit the FDA website.

Patients and physicians should refer to the following information before contacting us about potential Expanded Access / Compassionate Use opportunities.


http://www.ipharminc.com/expanded-access-and-compassionate-use/



To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.

Seems like an easy revenue stream to me.


Prurisol data coming VERY soon...
From December...
http://www.ipharminc.com/press-release/2017/12/21/innovation-pharmaceuticals-completes-final-patient-visit-in-phase-2b-study-of-oral-prurisol-for-psoriasis



MUST READ consolidated DD...

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138053364

Potential Milestones (Q1)

1. Prurisol - Topline Data (Phase 2b)
2. Kevetrin - Topline Data (Phase 2a)
3. B-OM - Breakthrough Therapy Designation


Kevetrin’s Effect on the p53 Signaling Pathway in a Broader Scientific Context :

http://www.ipharminc.com/new-blog/2017/12/27/kevetrins-effect-on-the-p53-signaling-pathway-in-a-broader-scientific-context